Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial Transcript
Good day, and thank you for standing by. Welcome to the 12-month top-line results of TOPAZ Phase II trial. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Catherine Hu, Vice President of Investor Relations and Communications. Please go ahead.
Good morning, and thank you for joining us on today's call to review the 12-month top-line results from our apitegromab TOPAZ Phase II clinical trial of patients with Type 2 and Type 3 spinal muscular atrophy, or SMA.
The webcast slides for this call can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.
I wanted to note that we'll be making various statements about Scholar Rock's future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |